RT Journal
A1 Nguyen PL, Je Y, Choueiri TK
T1 ANdrogen deprivation therapy for prostate cancer and cardiovascular death—reply
JF JAMA
JO JAMA
YR 2012
FD March 28
VO 307
IS 12
SP 1252
OP 1253
DO 10.1001/jama.2012.353
UL http://dx.doi.org/10.1001/jama.2012.353
AB 
In Reply: The physiological effects of ADT typically persist long after cessation of treatment, particularly in men older than 70 years who comprised the majority of patients in the trials included in our meta-analysis. Testosterone suppression often persists for 2 or more years after ADT is stopped.1- 3 Thus, the interval between ADT-induced testosterone suppression and data collection is actually shorter than it may appear. However, our study cannot rule out the possibility that fatal cardiac events could be occurring earlier in men exposed to ADT.